The present invention relates to monoclonal antibodies that specifically bind to human IL-1 R7, or a fragment or derivative thereof or a polypeptide that contain at least a portion of said antibody that is sufficient to confer specific IL-1 R7 binding to the polypeptide. The invention also relates to the use of said antibodies in the treatment of a IL-18 mediated disease and pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention.
